Neutrophil hitchhiking for drug delivery to the bone marrow

Nat Nanotechnol. 2023 Jun;18(6):647-656. doi: 10.1038/s41565-023-01374-7. Epub 2023 Apr 20.

Abstract

Pharmaceuticals have been developed for the treatment of a wide range of bone diseases and disorders, but suffer from problematic delivery to the bone marrow. Neutrophils are naturally trafficked to the bone marrow and can cross the bone marrow-blood barrier. Here we report the use of neutrophils for the targeted delivery of free drugs and drug nanoparticles to the bone marrow. We demonstrate how drug-loaded poly(lactic-co-glycolic acid) nanoparticles are taken up by neutrophils and are then transported across the bone marrow-blood barrier to boost drug concentrations in the bone marrow. We demonstrate application of this principle to two models. In a bone metastasis cancer model, neutrophil delivery is shown to deliver cabazitaxel and significantly inhibit tumour growth. In an induced osteoporosis model, neutrophil delivery of teriparatide is shown to significantly increase bone mineral density and alleviate osteoporosis indicators.

MeSH terms

  • Bone Marrow
  • Humans
  • Lactic Acid / therapeutic use
  • Nanoparticles*
  • Neutrophils
  • Osteoporosis* / drug therapy
  • Polyglycolic Acid / therapeutic use
  • Polylactic Acid-Polyglycolic Acid Copolymer

Substances

  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Lactic Acid
  • Polyglycolic Acid